Avalyn Pharma has completed enrolling 375 patients in its Phase 2b MIST trial testing AP01, an inhaled pirfenidone treatment for progressive pulmonary fibrosis (PPF). The trial aims to evaluate AP01's safety and effectiveness in preserving lung function over 52 weeks, with topline results expected in the second half of 2027. This milestone highlights strong demand for new PPF treatments, a condition with poor prognosis and limited options. Avalyn's inhaled therapy could offer improved tolerability and quality of life compared to existing oral treatments.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
